Coya Therapeutics, Inc. - COYA STOCK NEWS

Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotechnology company focused on regulatory T cell function enhancement, has announced its participation in the 7th Annual Evercore HealthCONx Conference. The event will take place from December 3-5, 2024, at the Loews Coral Gables Hotel in Florida.

CEO Arun Swaminathan and Executive Chairman Howard Berman will engage in a fireside chat on December 3 at 12:55 PM ET, moderated by Evercore ISI's Director Michael DiFiore. The executives will also be available for one-on-one meetings during the conference. The presentation will be accessible via webcast and archived for one year on Coya's website.

Coya Therapeutics (NASDAQ: COYA) has outlined its strategic plans for 2025, focusing on three key programs: ALS, FTD, and Alzheimer's disease. The company plans to submit data for its COYA 302 Phase 2 ALS trial by Q2 2025, expects topline results from FTD studies in H2 2025, and will disclose additional Alzheimer's disease data in H1 2025. The company's partnership with Dr. Reddy's Laboratories, worth up to $700 million, continues to strengthen, with an anticipated $8.4 million milestone payment upon ALS trial initiation. Coya maintains a strong cash position and is pursuing additional strategic partnerships across multiple indications.

Coya Therapeutics (NASDAQ: COYA) reported Q3 2024 financial results and corporate updates. Key highlights include positive results from a low-dose IL-2 study in Alzheimer's Disease, patent filings for COYA 301 with GLP-1 receptor agonists, and leadership changes with Arun Swaminathan becoming CEO. The company's cash position was $31.1 million as of September 30, 2024. Q3 net loss increased to $4.0 million from $3.4 million year-over-year. R&D expenses rose to $2.2 million from $1.6 million, while G&A expenses increased slightly to $2.2 million from $2.0 million.

Coya Therapeutics announces Arun Swaminathan, Ph.D., as new CEO effective November 1, 2024. Dr. Swaminathan, who previously led the company's $700 million potential licensing deal with Dr. Reddy's Laboratory, will guide Coya's growth in developing treatments for neurodegenerative diseases. The company also reported encouraging results from a Phase 2 investigator-initiated trial in Alzheimer's disease using low-dose interleukin-2 (LD IL-2). The trial showed cognitive stabilization and significant CSF biomarker improvement in the lower dose IL-2 arm, validating their Treg platform approach.

Coya Therapeutics (NASDAQ: COYA) announced positive results from a Phase 2 clinical trial of low-dose interleukin-2 (LD IL-2) in Alzheimer's Disease patients. The study met its primary safety endpoints and secondary endpoints for Regulatory T cell enhancement. The trial, involving 38 participants, tested two dosing regimens: every 4 weeks (q4wks) and every 2 weeks (q2wks). The q4wks dosing showed promising results, including cognitive stabilization and improved cerebrospinal fluid biomarkers. Notably, the q4wks group demonstrated a 4.93-point improvement in ADAS-Cog14 scores compared to placebo, and significant improvements in CSF Aβ42 levels. The treatment was well-tolerated with no serious adverse events reported.

Coya Therapeutics (NASDAQ: COYA) announces an upcoming conference call on Tuesday, October 29, at 8am ET to discuss results from a placebo-controlled, investigator-initiated Phase 2 clinical trial of low-dose interleukin-2 (LD IL-2) in patients with mild to moderate Alzheimer's Disease. The results will be simultaneously presented at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid, Spain. The study was led by Dr. Alireza Faridar and Dr. Stanley Appel from Houston Methodist Research Institute, with funding from the Alzheimer's Association, Gates Foundation, and National Institute on Aging.

Coya Therapeutics (Nasdaq: COYA) has completed a $10.0 million private placement through the sale of 1,379,314 shares of common stock at $7.25 per share. The majority of investors were existing institutional stockholders. As of September 30, 2024, the company reported preliminary unaudited cash and cash equivalents of approximately $31.0 million. The proceeds will support general corporate purposes, administrative expenses, working capital, and preclinical, clinical, and regulatory activities for their product pipeline. BTIG, led the placement, with Allele Capital Partners and Chardan as co-placement agents.

Coya Therapeutics (Nasdaq: COYA), a clinical-stage biotechnology company focused on enhancing regulatory T cell function, has announced a $10.0 million private placement. The company will sell 1,379,314 shares of common stock at $7.25 per share to primarily existing institutional stockholders. The offering is expected to close around October 23, 2024, subject to customary conditions.

BTIG, is leading the placement, with Allele Capital Partners, and Chardan Capital Markets as co-placement agents. Coya plans to use the net proceeds for general corporate purposes, including administrative expenses, working capital, and supporting preclinical, clinical, and regulatory activities for their product pipeline.

The securities are being offered privately under Section 4(a)(2) of the Securities Act and Regulation D, and are not registered for public sale. Coya has agreed to file a registration statement with the SEC for resale of these securities within 30 days of the definitive agreements.

Coya Therapeutics (NASDAQ: COYA) announces that its Chairman and CEO, Howard Berman, Ph.D., has been recognized as a PharmaVoice 100 winner in the category of Biotech Pathfinders. This annual list honors the most inspiring individuals in the life sciences industry. The recognition comes as Dr. Berman prepares to transition to Executive Chairman on Nov. 1, as previously announced.

Arun Swaminathan, Ph.D., Coya's current Chief Business Officer and incoming CEO, praised Dr. Berman's leadership in building Coya from a startup to a clinical-stage company with promising candidates for neurodegenerative diseases. The PharmaVoice 100 honors individuals across various categories, recognizing their transformative impact on the pharmaceutical industry.